Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Pharmapack Europe (6-7 February, Paris Expo Porte de Versailles, Paris) has released a ‘European Drug Delivery and Packaging’ report, ahead of the event’s opening which highlights, major challenges and opportunities for the industry in the year ahead.

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

The report forecasts increased innovation by smaller companies across Europe, as industry leaders and executives prepare to meet at Europe’s biggest pharma packaging and drug delivery event. The primary drivers for the rise in innovation were attributed to an overall increase in biologics, which is bringing investment into newer drug delivery systems such as auto-injectors, and the opening up of digital technologies across the internet of medical things (IoMT) and connected devices.

In Europe, emphasised by Pharmapack’s own Innovation Gallery, a large number of smaller and highly agile firms are developing these more specialised and consumer-friendly technologies. Many of the report’s experts, however, tempered excitement with the acknowledgement that there still remains a big scale-up gap between promising prototypes and commercial products. As a result, it is likely that that the larger drug delivery manufacturers and pharma companies will scour these new innovation hubs for licensing partners and acquisitions. Ultimately, these new combinations of small and large companies should help accelerate and enable ground-breaking technologies to reach the patient without becoming slowed by scale-up challenges or regulatory approvals.

The report also includes the first ever ‘drug delivery innovation’ rankings, with a clear tier-one of European nations emerging – with Germany heading the rankings narrowly followed by France, Switzerland, and the UK. Globally, the rankings were headed by Japan and the US.

Another key market trend is new delivery technologies to help patients self-administer drugs – such as pre-filled, needle-free delivery – and smart applications that help patients to monitor dosing and time of delivery. It is a particularly significant trend, as healthcare prices continue to rise globally, and delivery mechanisms remove the need for supervision of a healthcare professional. This will help reduce the overall cost burden in public and private health economies. In the report, Andy Fry, Founder of Team Consulting comments: “The balance between sales of ‘conventional’ and ‘biologic’ drugs have shifted progressively over the past few years. Given that virtually all biologics are parenterally delivered, the majority of these self-administered, the strong demand for wearable delivery devices, autoinjectors and pens, as well as pre-filled syringes and dual chamber products, is expected to continue in 2019.”

Fiona Barry, Associate Editor of PharmSource, a GlobalData Product, warns the impending exit of the UK from the European Union could affect the UK’s dominant position as a manufacturer of advanced therapies. Within Europe, a disproportionate number of these therapies are produced in the UK, but this could shift to Germany, the Netherlands, and Belgium post-Brexit, she said. Reflecting these trends, Fabien Roy, Counsel at Hogan Lovells International LLP, will chair a panel discussion at Pharmapack Europe to discuss the practical implications of Brexit for pharmaceutical and medical device companies. In packaging, serialisation is now coming into effect and experts highlighted concerns that, despite the long run-up, many small companies may not be well prepared for the full implementation of regulations.

The Pharmapack Europe report concludes the combined trends of the drug delivery and packaging sector over the next few years demonstrate a clear desire from regulators, developers and patients to improve the overall patient experience and centralize treatment options around the patient. In Europe, this aspiration, coupled with a growth in biologics manufacturing and a new age of innovation is redefining the art of the possible and reimagining delivery and adherence options. In fact, we would predict that a number of new innovation hubs will emerge, with a more diverse range of companies. The net results of this are likely to be an increase in licensing deals between small and large firms, as well as numerous acquisitions and co-development deals.

Silvia Forroova, Event Director Pharmapack, commented: “Our report’s findings closely mirror the agenda we have developed, and the conference will run across three broad themes – ‘patient adherence and usability’, ‘new packaging materials and drug delivery systems’, and ‘sustainability’. Our sessions on patient-centricity, smart devices and packaging, as well as connected applications and auto-injectors are generating particular excitement.”

To take just a snapshot of trends emerging at the event, Pharmapack Europe will explore the commercial drivers behind ‘the future of Smart Packaging and Design’ with analysis provided by Dr Alex Cole of the UK’s Centre for Process Innovation. Dr David Braun, Global Head of Device solutions at Merck – one of the experts to contribute in the report – will deliver a session on the ‘real value of connected devices’. In-patient centricity, Giana Carli Lorenzini of Lund University will explore the ‘potential challenges to design and innovation’, and how these can be overcome.

Forroova added: We have witnessed first-hand more pharma and medical device companies specifically coming to Pharmapack Europe to explore what the next wave of clinical developments are, and to discover new innovations. So, while the last 2 years have been a golden period for FDA approvals, with record numbers achieved, the next 5 years are expected to be the golden period of innovation for drug delivery and packaging across Europe. What is most exciting about all these changes, when looked at collectively, is that there is an increasing diversification of the types of companies, types of professionals, and collaborations in the industry driving innovation forward. Other industries have clearly shown that when an open-access approach to new technologies is taken, transformational changes are often quick to follow. It really is an exciting time to be hosting the industry here in Paris.”

The conference agenda also features sessions on serialization, as well as sustainability, QbD, combination products and long-acting injectables. The final day of the event will see an in-depth exploration of biosimilars and the outlook for innovative biologicals, and crucially, what the implications are for packaging and dose delivery.

Read More

Related news

Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Univercells introduces breakthrough vaccine manufacturing platform

Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more 
One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Global pharma set for strong year

Global pharma set for strong year

23 Oct 2018

Eight of the top ten pharma nations reporting improving market conditions.

Read more